Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ribavirin,ritonavir -

European Union - English - EMA (European Medicines Agency)

abbvie ltd - ombitasvir / paritaprevir / ritonavir - hepatitis c, chronic - antivirals for systemic use - viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ombitasvir,paritaprevir,ritonavir -

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir dihydrate,ribavirin,ritonavir -

United States - English - NLM (National Library of Medicine)

abbvie inc. - ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ombitasvir 12.5 mg - viekira pak is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration ( 2.2 ) and clinical studies ( 14 )] : - genotype 1b without cirrhosis or with compensated cirrhosis - genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira pak is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira pak is contraindicated: ○ in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions ( 5.2 ), use in specific populations ( 8.6 ) and clinical pharmacology ( 12.3 )] . ○ with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions ( 7 ) and clinical pharm